Concord Biotech share price
Concord Biotech Ltd. · NSE: CONCORDBIO · Healthcare
Price, one year
Price range
- Open
- ₹1,270.50
- High
- ₹1,279.70
- Low
- ₹1,212.50
- Previous close
- ₹1,270.70
- Volume
- 69,997
- Market cap
- ₹12,896 Cr
Key statistics
Results to 30 Jun 2026 · Consolidated- P/E (TTM)
- 48.7
- Price to book
- 6.6
- Return on equity
- 13.7%
- EPS (TTM)
- ₹26.09
- Book value / share
- ₹192.81
- Debt to equity
- 0.00
- Revenue (TTM)
- ₹1,108 Cr
- Net profit (TTM)
- ₹275 Cr
- Sales growth, YoY
- +26.2%
- Profit growth, YoY
- +32.8%
- Operating margin
- 35.0%
- Net margin
- 24.8%
- Sales CAGR, 3 years
- —
- Profit CAGR, 3 years
- —
- Promoter holding
- 44.09%
- Promoter shares pledged
- 0.00%
Shareholding pattern
% of shares| Holder | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 44.08 | 44.08 | 44.09 |
| Foreign institutions | 7.80 | 7.52 | 7.28 |
| Domestic institutions | 9.22 | 9.36 | 10.95 |
| Mutual funds | 4.30 | 4.40 | 5.84 |
| Retail and others | 8.09 | 8.23 | 8.81 |
Results and announcements
Latest results (quarter to 30 Jun 2026) filed 31 Jul 2026. results: 27 Oct 2026.
Peers in Healthcare
All Healthcare stocks| Company | Price | Change |
|---|---|---|
| Sun Pharmaceutical IndustriesSUNPHARMA | ₹1,740.40 | −1.00% |
| Divi's LaboratoriesDIVISLAB | ₹8,881.00 | −3.07% |
| Torrent PharmaceuticalsTORNTPHARM | ₹4,487.80 | −2.76% |
| Zydus LifesciencesZYDUSLIFE | ₹1,124.80 | −0.90% |
| Apollo Hospitals EnterpriseAPOLLOHOSP | ₹7,584.50 | −0.26% |
| CiplaCIPLA | ₹1,319.30 | −0.87% |
| Laurus LabsLAURUSLABS | ₹1,943.10 | −2.97% |
| Dr. Reddy's LaboratoriesDRREDDY | ₹1,226.70 | −0.99% |
| Mankind PharmaMANKIND | ₹2,228.10 | −2.09% |
| Aurobindo PharmaAUROPHARMA | ₹1,557.50 | −3.31% |
Frequently asked questions
What is the share price of Concord Biotech today?
Concord Biotech (NSE: CONCORDBIO) was at ₹1,232.70 on 23 Oct 2026, a change of −2.99% from the previous close.
What are the 52-week high and low of Concord Biotech?
Over the last 52 weeks Concord Biotech traded between ₹987.00 and ₹1,615.00 (daily highs and lows on NSE on 23 Oct 2026).
What is the market capitalisation of Concord Biotech?
About ₹12,896 Cr at the latest price, with a P/E of 48.7, a price-to-book of 6.6, a return on equity of 13.7%. Ratios use the company's latest reported results.
Who owns Concord Biotech shares?
According to the shareholding pattern filed with the exchange at the end of the quarter to 30 Sep 2026, promoters held 44.09%, foreign institutions 7.28%, domestic institutions 10.95%.
Which sector and indices does Concord Biotech belong to?
NSE classifies Concord Biotech under Healthcare; it is a member of Nifty 500.
Follow Concord Biotech with research you can verify. Add it to a watchlist, see screens and charts, and get calls from SEBI-registered research analysts with recorded track records.
Get started free